Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3018]

The translational element of the WIN consortium

Dr Brian Leyland-Jones - WIN Head of Fundraising Committee

The translational element of the WIN consortium ( Dr Brian Leyland-Jones - WIN Head of Fundraising Committee )

How the WIN consortium achieves its goals

Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA

How the WIN consortium achieves its goals ( Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA )

Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive...

Prof Tony Mok - Chinese University of Hong Kong, Hong Kong

Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) with PD-L1 advanced NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Hong Kong )

Using CT imaging to find radiomic signatures in surgically resected NSCLC

Giulia Mazzaschi - University Hospital Parma, Parma, Italy

Using CT imaging to find radiomic signatures in surgically resected NSCLC ( Giulia Mazzaschi - University Hospital Parma, Parma, Italy )

The role of afatinib in patients with EGFR NSCLC

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

The role of afatinib in patients with EGFR NSCLC ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )

Biomarkers of systemic inflammation linked to reduced clinical activity of...

Luciana Molinero - Genentech, San Francisco, USA

Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC ( Luciana Molinero - Genentech, San Francisco, USA )

ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory...

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

$ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )$

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative...

Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA

Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer ( Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA )

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non...

Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer ( Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA )

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2...

Prof Shoba Navai - Baylor College of Medicine, Houston, USA

Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET...

Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA

TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1...

Dr James Gulley - National Cancer Institute, Bethesda, USA

Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )

More from ecancer